Want to see SE:AMBEA full AI Analyst Report?
Top Page
Ambea AB
(AMBEA)
Select Model
Select Model
Rating:68Neutral
Price Target:
kr181.00
▲(29.10% Upside)
Action:Reiterated
Date:08/20/26
The score is driven primarily by solid operating performance and strong free cash flow quality, tempered by elevated leverage that increases financial risk. Technicals are constructive with price above key moving averages, while valuation is fair but not compelling given a mid-range P/E and modest dividend yield.
Positive Factors
Steady Revenue Growth
Sustained revenue expansion supports Ambea’s long-term growth profile and reflects continued demand for Nordic care services. Growth across contracted and facility-based activities can improve operating scale and strengthen cash generation.
Negative Factors
Elevated Leverage
High debt relative to equity increases financial risk and limits flexibility if operating conditions weaken. It may constrain investment, acquisitions or shareholder distributions while making the business more dependent on stable cash flows and refinancing access.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Sustained revenue expansion supports Ambea’s long-term growth profile and reflects continued demand for Nordic care services. Growth across contracted and facility-based activities can improve operating scale and strengthen cash generation.
Read all positive factors
Ambea AB (AMBEA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr13.04B
Dividend Yield1.53%
Average Volume (3M)135.59K
Price to Earnings (P/E)18.2
Beta (1Y)0.62
Revenue Growth13.33%
EPS Growth28.61%
CountrySE
Employees41,000
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)9.55
Shares Outstanding80,384,420
10 Day Avg. Volume127,005
30 Day Avg. Volume135,589
Financial Highlights & Ratios
PEG Ratio1.73
Price to Book (P/B)2.27
Price to Sales (P/S)0.74
P/FCF Ratio5.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.38
Revenue Forecast (FY)kr17.60B
Ambea AB Business Overview & Revenue Model
Company Description
Ambea AB (publ) provides extensive health and social care provisions, encompassing accommodation, support services, educational offerings, and qualified personnel, to senior citizens and individuals with disabilities throughout Sweden, Norway, and...
How the Company Makes Money
Ambea makes money primarily by delivering publicly funded care services under contracted arrangements with municipalities, regions, and other public purchasers in the Nordic welfare system. Revenue is generated when the company operates care facil...
Ambea AB Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
48
Neutral
Cash Flow
79
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.91B | 16.04B | 14.20B | 13.31B | 12.63B | 11.48B |
| Gross Profit | 5.22B | 2.81B | 2.44B | 3.44B | 12.19B | 11.06B |
| EBITDA | 2.70B | 2.71B | 2.61B | 2.28B | 2.04B | 1.61B |
| Net Income | 788.00M | 665.00M | 620.00M | 455.00M | 366.00M | 237.00M |
Balance Sheet | ||||||
| Total Assets | 21.04B | 20.48B | 18.48B | 17.89B | 17.88B | 16.67B |
| Cash, Cash Equivalents and Short-Term Investments | 62.00M | 133.00M | 28.00M | 6.00M | 259.00M | 86.00M |
| Total Debt | 13.21B | 12.64B | 11.05B | 10.74B | 10.96B | 9.89B |
| Total Liabilities | 15.90B | 15.28B | 13.49B | 12.97B | 13.19B | 12.14B |
| Stockholders Equity | 5.14B | 5.20B | 4.99B | 4.92B | 4.68B | 4.53B |
Cash Flow | ||||||
| Free Cash Flow | 2.20B | 2.03B | 1.95B | 1.62B | 1.33B | 1.11B |
| Operating Cash Flow | 2.33B | 2.17B | 2.07B | 1.71B | 1.44B | 1.21B |
| Investing Cash Flow | -290.00M | -1.39B | -358.00M | -93.00M | -214.00M | -258.00M |
| Financing Cash Flow | -2.21B | -672.00M | -1.69B | -1.88B | -1.04B | -882.00M |
Ambea AB Technical Analysis
Positive
140.20
Price Trends
146.59
Positive
143.11
Positive
136.63
Positive
Market Momentum
7.72
Negative
74.63
Negative
88.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:AMBEA, the sentiment is Positive. The current price of 140.2 is below the 20-day moving average (MA) of 151.69, below the 50-day MA of 146.59, and above the 200-day MA of 136.63, indicating a bullish trend. The MACD of 7.72 indicates Negative momentum. The RSI at 74.63 is Negative, neither overbought nor oversold. The STOCH value of 88.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:AMBEA.
Ambea AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | kr3.37B | 20.25 | 5.55% | 2.18% | -3.48% | -14.02% | |
68 Neutral | kr13.04B | 18.19 | 13.73% | 1.89% | 13.33% | 28.61% | |
67 Neutral | kr7.65B | 19.76 | 5.03% | 3.60% | -3.08% | -10.70% | |
66 Neutral | kr18.90B | 46.06 | 5.17% | ― | 7.86% | 55.47% | |
65 Neutral | kr18.00B | 17.90 | ― | 0.82% | -1.07% | 81.76% | |
64 Neutral | kr36.70B | 39.13 | ― | 1.01% | 5.73% | 90.34% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:AMBEA
Ambea AB
173.70
48.50
38.74%
SE:MCOV.B
Medicover AB
243.00
-19.75
-7.52%
SE:ATT
Attendo AB
119.20
53.97
82.74%
SE:ARJO.B
Arjo AB
28.06
-5.43
-16.20%
SE:HUM
Humana AB
71.50
32.07
81.33%
SE:VIMIAN
Vimian Group AB
35.55
3.99
12.64%
Ambea AB Corporate Events
Ambea posts strong Q2 and moves to acquire Humana in Nordic care push
Aug 19, 2026
Ambea reported a strong second quarter of 2026, underlining solid growth, improved profitability and robust cash generation across its Nordic operations. Net sales rose 7% to SEK 4,387 million, with adjusted EBITA margin improving to 9.0%, driven ...
Ambea Launches Share Buyback to Support Humana Takeover Bid
Jun 29, 2026
Ambea AB’s board has approved a share repurchase program of up to 5,560,658 shares, representing a portion of its 80,384,424 outstanding shares, to support its recommended public offer for Humana AB. The buyback, authorised until the 2027 an...
Ambea launches recommended bid for Humana in Nordic care sector shake-up
Jun 29, 2026
Ambea has launched a recommended public offer to acquire all shares in rival care provider Humana AB, proposing a mix of SEK 20 in cash, 0.305 Ambea shares and a contingent value right for each Humana share. The bid, valuing Humana at about SEK 2....
Ambea launches public offer to acquire Humana and expand Nordic care footprint
Jun 29, 2026
Ambea AB has announced a public offer to the shareholders of Humana AB to tender all their shares, with the intention of combining the two care companies. The move signals Ambea’s ambition to strengthen its position in the Nordic care market...
Ambea Expands Danish Footprint With New 88-Bed Care Home in Nivå
Jun 15, 2026
Ambea, via its Danish subsidiary Altiden, has agreed to establish a new 88-bed care home in Nivå in Fredensborg Municipality, Denmark, scheduled to open to residents in 2028. The project, developed in partnership with local authorities and pr...
Ambea expands Finnish child and youth care with Ehot acquisition
Jun 1, 2026
Ambea is expanding its Nordic care footprint through its Finnish unit Validia by acquiring the business operations of Ehot Ltd, a provider of foster care and residential services for children and young people with extensive support needs. The deal...
Ambea Refines Capital Structure After Warrant Exercises and Share Cancellation
May 29, 2026
Ambea AB has adjusted its share structure following the exercise of warrants under its 2023/2026 incentive program and the cancellation of repurchased shares. The company now has a total of 80,384,424 shares and votes, with registered share capita...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.